A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL

Prior treatment

• Prior treatment with a MALT1 inhibitor
• Patient receiving any other investigational drug within 4 weeks prior to study entry

Other illness

• History of lymphoid malignancy other than those allowed per inclusion criteria
• Patient with systemic and active infection
• Any serious or uncontrolled medical disorder that may increase the risk associated with study participation or study treatment, or interfere with the interpretation of study results

Other

• Patient with central nervous system involvement
• Patient is unable to swallow tablets
• Patient is found to be otherwise ineligible for the study by the investigator or sub investigator

• Patient aged ≥ 18 years
• Written informed consent by the patient or the patient's legally authorized representative
• Patient with histologically/cytologically confirmed diagnosis of NHL or CLL
• Patient with relapsed or refractory disease who has no available therapeutic options known to provide clinical benefit
• Patient who has measurable disease
• All acute toxic effects of any prior antitumor therapy, including investigational therapy, resolved to Grade ≤ 1 before the start of study therapy
• Eastern Cooperative Oncology Group Performance Status 0 to 2
• Adequate bone marrow, renal and hepatic functions